Drug Pipeline

Satralizumab Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
7
Active Studies
2
Recruiting
5
Phase 3
2
Top Sponsors
6
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-09 NCT05271409
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of…		 overall status: "Recruiting" → "Active Not Recruiting"
2026-06-09 NCT05271409
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of…		 Trial sites reduced: 82 -> 54 locations
2026-06-09 NCT05503264
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics…		 Enrollment reduced: 152 -> 120 participants
2026-06-09 NCT05503264
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics…		 date change Completion moved earlier: 2029-12-14 -> 2028-12-14
2026-05-16 NCT06450639
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy…		 Primary endpoint(s) modified
2026-05-16 NCT06450639
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy…		 Trial sites reduced: 22 -> 19 locations
Active Studies by Phase
Phase 4
1
Phase 3
5
Phase 2
1
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT07010302 Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD NMOSD Not Yet Recruiting
Phase 3
NCT05503264 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics… NMDAR Autoimmune Encephalitis Recruiting
NCT05199688 A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And… Neuromyelitis Optica Spectrum Disorder Recruiting
NCT05987423 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of… Thyroid Eye Disease Active, Not Recruiting
NCT06106828 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of… Thyroid Eye Disease Active, Not Recruiting
NCT05271409 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of… Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) Active, Not Recruiting
Phase 2
NCT06450639 A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy… Duchenne Muscular Dystrophy Active, Not Recruiting
Sponsors Running Satralizumab Trials
Hoffmann-La Roche (6) Massachusetts General Hospital (1)
Disease Areas
Duchenne Muscular Dystrophy (1)
Get alerts when Satralizumab trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free